The invention relates to crystalline forms of Alpha-1062 gluconate. In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form C), wherein said crystalline form has prominent peaks at 3.90, 9.74, 10.35 and 21.43 degrees 2-theta (0.2) in a powder X-ray diffraction pattern. The invention further relates to methods for treating a brain disease associated with cognitive impairment and/or with a cholinergic deficit in a subject, including administering the crystalline forms of Alpha-1062 gluconate to a subject in need thereof.

The invention provides novel chemical compounds useful for treating one or more of autoimmune diseases, cancer, cardiovascular diseases, inflammatory diseases and diabetes, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

The invention provides novel chemical compounds useful for treating one or more of autoimmune diseases, cancer, cardiovascular diseases, inflammatory diseases and diabetes, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan characteristics can be provided.

A visible light activated ink that produces a color change when exposed to visible light is provided. The ink includes a visible light activated photochromic compound, one or more binders, additives including one or more surfactants, and a solvent. The visible light activated ink is substantially colorless in the as-deposited state and requires a visible light intensity of approximately 300 W/m.sup.2 or greater at a wavelength of approximately 400-700 nm to produce a color change.

A visible light activated ink that produces a color change when exposed to visible light is provided. The ink includes a visible light activated photochromic compound, one or more binders, additives including one or more surfactants, and a solvent. The visible light activated ink is substantially colorless in the as-deposited state and requires a visible light intensity of approximately 300 W/m.sup.2 or greater at a wavelength of approximately 400-700 nm to produce a color change.

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

##STR00001##

where A, B, R.sub.1, X.sub.1, X.sub.2, and W are described herein.

The present invention relates to a cyanoaryl substituted compound of formula (I), (I) wherein m is 0-4; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are selected from hydrogen, chlorine, bromine and C.sub.6-C.sub.24-aryl, which carries one to three cyano; each R.sup.1 independently from each other is selected from bromine, chlorine, cyano, NRaRb, C.sub.1-C.sub.24-alkyl, C.sub.1-C.sub.24-haloalkyl, C1-C24-alkoxy, C.sub.1-C.sub.24-haloalkoxy, C.sub.3-C.sub.24-cycloalkyl, heterocycloalkyl, heteroaryl, C.sub.6-C.sub.24-aryl, C.sub.6-C.sub.24-aryloxy, C.sub.6-C.sub.24-aryl-C.sub.1-C.sub.10-alkylene, etc., with the proviso that at least one of the radicals R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is C.sub.6-C.sub.24-aryl, which carries one to three cyano; X is O, S, SO or SO.sub.2; A is a diradical of the formulae (A.1), (A.2), (A.3), or (A.4) wherein *, R.sup.6, (R.sup.7)n, (R.sup.8)o and (R.sup.9)p are as defined in the claims and in the description. The invention also relates to the use of said compound(s) in color converters, to said color converters and their use, to lighting devices, to a backlight unit for liquid crystal displays; a liquid crystal display device and a self-emissive display device comprising at least one compound (I).

##STR00001##

The present invention relates to a cyanoaryl substituted compound of formula (I), (I) wherein m is 0-4; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are selected from hydrogen, chlorine, bromine and C.sub.6-C.sub.24-aryl, which carries one to three cyano; each R.sup.1 independently from each other is selected from bromine, chlorine, cyano, NRaRb, C.sub.1-C.sub.24-alkyl, C.sub.1-C.sub.24-haloalkyl, C1-C24-alkoxy, C.sub.1-C.sub.24-haloalkoxy, C.sub.3-C.sub.24-cycloalkyl, heterocycloalkyl, heteroaryl, C.sub.6-C.sub.24-aryl, C.sub.6-C.sub.24-aryloxy, C.sub.6-C.sub.24-aryl-C.sub.1-C.sub.10-alkylene, etc., with the proviso that at least one of the radicals R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is C.sub.6-C.sub.24-aryl, which carries one to three cyano; X is O, S, SO or SO.sub.2; A is a diradical of the formulae (A.1), (A.2), (A.3), or (A.4) wherein *, R.sup.6, (R.sup.7)n, (R.sup.8)o and (R.sup.9)p are as defined in the claims and in the description. The invention also relates to the use of said compound(s) in color converters, to said color converters and their use, to lighting devices, to a backlight unit for liquid crystal displays; a liquid crystal display device and a self-emissive display device comprising at least one compound (I).

##STR00001##

The disclosure includes compounds of Formula (I)

##STR00001## wherein R.sub.0, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and L are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.